People: Trovagene Inc (TROV.PH)

TROV.PH on Philadelphia Stock Exchange

6.47USD
3:46pm EDT
Price Change (% chg)

$-0.28 (-4.15%)
Prev Close
$6.75
Open
$6.59
Day's High
$6.59
Day's Low
$6.47
Volume
200
Avg. Vol
18
52-wk High
$8.20
52-wk Low
$3.14

Search Stocks

Summary

Name Age Since Current Position

Thomas Adams

 70 2009 Independent Chairman of the Board

Antonius Schuh

 49 2011 Chief Executive Officer, Director

Stephen Zaniboni

 54 2012 Chief Financial Officer

Mark Erlander

 2013 Chief Scientific Officer

Gabriele Cerrone

 40 2010 Director

Christopher McGuigan

 54 2013 Director

John Brancaccio

 65 2005 Independent Director

Gary Jacob

 65 2009 Independent Director

Stanley Tennant

 61 2010 Independent Director

Amy Caterina

 IR Contact Officer
» Insider Trading

Biographies

Name Description

Thomas Adams

 Dr. Thomas H. Adams, Ph.D., serves as Independent Chairman of the Board of TrovaGene Inc. Since June 2005, Dr. Adams has served as a director of IRIS International, Inc., a diagnostics company, and as Chief Technology Officer of IRIS since April 2006. Dr. Adams served as Chairman and Chief Executive Officer of Leucadia Technologies, a privately held medical-device company, from 1998 to April 2006, when Leucadia was acquired by IRIS. In 1989, Dr. Adams founded Genta, Inc., a publicly held biotechnology company in the field of antisense technology, and served as its Chief Executive Officer until 1997. Dr. Adams founded Gen-Probe, Inc. in 1984 and served as its Chief Executive Officer and Chairman until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Before founding Gen-Probe, Dr. Adams held management positions at Technicon Instruments and the Hyland Division of Baxter Travenol. He has public-company experience serving as a director of Biosite Diagnostics, Inc., a publicly held medical research firm, from 1989 to 1998 and as a director of Invitrogen, a publicly held company that develops, manufactures and markets research tools and products, from 2000 to 2002. Dr. Adams is currently a director of Synergy Pharmaceuticals, Inc., a biotechnology company. Dr. Adams holds a Ph.D. in Biochemistry from the University of California, at Riverside.

Antonius Schuh

 Dr. Antonius P. Schuh, Ph.D., serves as Chief Executive Officer, Director of TrovaGene Inc. He joined the company in October 2011 as Chief Executive Officer and was elected as a Director in December 2011. Dr. Schuh co-founded Sorrento Therapeutics, Inc., a biopharmaceutical company developing monoclonal antibodies, in January 2006. From such time until April 2011, he served as Chairman of the Board and Chief Executive Officer from November 2008 to April 2011. From April 2006 to September 2008, Dr. Schuh served as Chief Executive Officer of AviaraDx (now bioTheranostics, Inc., a bioMerieux company), a molecular diagnostic testing company that is focused on clinical applications in oncology. From March 2005 to April 2006, Dr. Schuh was Chief Executive Officer of Arcturus Bioscience Inc., a developer of laser capture microdissection and reagent systems for microgenomics. From December 1996 to February 2005, Dr. Schuh was employed by Sequenom Inc., a publicly traded diagnostic testing and genetics analysis company. He started with Sequenom as a Managing Director and was promoted to Executive Vice President, Business Development and Marketing, and from May 2000 to February 2005, served as Sequenom's President and Chief Executive Officer. He also previously served as the Head of Business Development at Helm AG, an international trading and distribution corporation for chemical and pharmaceutical products, and in medical and regulatory affairs positions with Fisons Pharmaceuticals (now part of Sanofi-Aventis). Since March 2009, Dr. Schuh has been appointed to the board of directors of Diogenix, Inc., a privately held molecular diagnostic company, and since May 2009, he has served as a director of Transgenomic, Inc., a public biotechnology company focused on genetic analysis and molecular diagnostics. Dr. Schuh is a certified pharmacist and earned his Ph.D. in pharmaceutical chemistry from the University of Bonn, Germany.

Stephen Zaniboni

 Mr. Stephen Zaniboni serves as Chief Financial Officer of TrovaGene Inc. Prior to joining the company, since June 2010, Mr. Zaniboni has served as Chief Financial Officer of Awarepoint Corporation, a provider of healthcare software. Prior to joining Awarepoint Corporation, Mr. Zaniboni served as Chief Financial Officer of XIFIN Inc., the provider of revenue cycle management for diagnostic service providers, from January 2009 through June 2010. Prior to joining XIFIN Inc. Mr. Zaniboni served as the Chief Financial Officer of Sorrento Therapeutics, Inc. from January 2006, and as a member of its board of directors from November 2008, through September 2009. From May 2006 to September 2008, Mr. Zaniboni served as Chief Financial Officer of AviaraDx (now bioTheranostics, a bioMerieux company), a molecular diagnostic testing cancer profiling company that is focused on developing and commercializing molecular diagnostic technologies with proven clinical utility. From October 2005 to April 2006, Mr. Zaniboni was Chief Financial Officer of Arcturus Bioscience (acquired by Molecular Devices Corp., now MDS). He joined Arcturus from Sequenom, Inc., a publicly traded diagnostic testing and genetics analysis company, where he served as Chief Financial Officer from May 1997 to September 2005. Mr. Zaniboni has also held various financial management positions at Aspect Medical Systems, Behring Diagnostics, and Boston Scientific. He was a practicing CPA with Arthur Andersen and holds a B.S. in accounting from Boston University and an M.B.A. from Boston College.

Mark Erlander

 Dr. Mark Erlander, Ph.D., is appointed as the Chief Scientific Officer of Trovagene, Inc. Dr. Erlander previously served as chief scientific officer of bioTheranostics (a bioMerieux company), a molecular oncology diagnostics laboratory based in San Diego. Prior to bioTheranostics, Dr. Erlander was a research fellow at the R.W. Johnson Pharmaceutical Research Institute (Johnson & Johnson). Earlier in his career, he was a postdoctoral fellow in the Department of Molecular Biology at The Scripps Research Institute, La Jolla. Dr. Erlander holds a BS degree in Biochemistry from the University of California, Davis; a MS degree in Biochemistry from Iowa State University; and a Ph.D. in Neuroscience from the University of California, Los Angeles. He holds 38 issued U.S. patents in the areas of diagnostics, therapeutics and genomic technologies, and is an author of 73 scientific publications with 56 peer-reviewed original articles and 17 review/chapter publications.

Gabriele Cerrone

 Mr. Gabriele M. Cerrone serves as Director of TrovaGene Inc. Since July 2008, Mr. Cerrone has served as Chairman of the Board of Directors and a consultant with Synergy Pharmaceuticals, Inc., a biotechnology company. From March 1999 to January 2005 Mr. Cerrone served as a Senior Vice President of Investments of Oppenheimer & Co. Inc., a financial services firm. In May 2001, Mr. Cerrone led the restructuring of SIGA Technologies, Inc., a biotechnology company, and served on its board of directors from May 2001 to May 2003. Mr. Cerrone also co-founded FermaVir Pharmaceuticals, Inc., a biotechnology company, and served as Chairman from August 2005 to September 2007, when the company was acquired by Inhibitex, Inc., a biotechnology company. Mr. Cerrone served as a director of Inhibitex, Inc. from September 2007 until February 2012 when it was acquired by Bristol-Myers Squibb Company. Since 2003, Mr. Cerrone has been Chairman of Callisto Pharmaceuticals, Inc., a biotechnology company, and a consultant to Callisto since 2005. Mr. Cerrone is the managing partner of Panetta Partners Ltd., a limited partnership that is a private investor in both public and private venture capital in the life sciences and technology arena as well as real estate.

Christopher McGuigan

 Dr. Christopher McGuigan is appointed as the Director of Trovagene, Inc. Since 1995, Dr. McGuigan has been Professor, Welsh School of Pharmacy, Head of Medicinal Chemistry, at Cardiff University, UK. In 2011 he was appointed Deputy Pro Vice Chancellor to the University and in 2012 he was appointed Pro Vice Chancellor. He is also a member of the Editorial Board for the Journal of Molecular Pharmaceutics and is the past President of the International Society for Antiviral Research. Dr. McGuigan is a director of Synergy Pharmaceuticals Inc., a biotechnology company. Dr. McGuigan received a B.S. and Ph.D. in Anticancer Drug Design from the University of Birmingham.

John Brancaccio

 Mr. John P. Brancaccio serves as Independent Director of TrovaGene Inc. Since April 2004, Mr. Brancaccio has been the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies. From May 2002 until March 2004, Mr. Brancaccio was the Chief Financial Officer of Memory Pharmaceuticals Corp., a biotechnology company. From 2000 to 2002, Mr. Brancaccio was the Chief Financial Officer/Chief Operating Officer of Eline Group, an entertainment and media company. Mr. Brancaccio is currently a director of Alfacell Corporation as well as a director of Synergy Pharmaceuticals, Inc. and Callisto Pharmaceuticals, Inc.

Gary Jacob

 Dr. Gary S. Jacob, Ph.D., serves as Independent Director of TrovaGene Inc. Since July 2008, Dr. Jacob has been President, Chief Executive Officer and a Director of Synergy Pharmaceuticals Inc. and as Chairman of a subsidiary of Synergy from October 2003 until July 2008. Dr. Jacob currently serves as Chief Executive Officer and a director of Callisto Pharmaceuticals, Inc. Dr. Jacob has over twenty-five years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research & development, operations and business development. Prior to 1999, Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 was Director of Functional Genomics, Corporate Science & Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England.

Stanley Tennant

 Dr. Stanley Tennant serves as Independent Director of TrovaGene Inc. Since 1983, Dr Tennant has been a cardiologist in Greensboro, NC. He graduated from Wake Forest University School of Medicine in 1978 and completed postgraduate training in Internal Medicine and Cardiology at Vanderbilt University in 1983.

Amy Caterina

Insider Trading

Name Shares Traded Price

CERRONE GABRIELE M

 40,000 $0.00

TENNANT STANLEY

 25,000 $4.82

CERRONE GABRIELE M

 7,500 $2.36

CERRONE GABRIELE M

 300 $2.15

CERRONE GABRIELE M

 15,000 $2.24

CERRONE GABRIELE M

 200,000 $0.50

TENNANT STANLEY

 100,000 $0.50

HUNTER ROBERT MERRILL

 400,000 $0.50
» Full list on Insider Trading
Search Stocks